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Since most HSC transplants using unrelated donors have HLA
mismatches between the recipient and donor, better approaches
for identifying the optimal donor amongst several mismatched can-
didates would be a major advance. The long-term goal of this inves-
tigation is to rank HLA disparities according to their effects on
transplant outcomes. In this report, HLA-A is used as a model to
characterize HLA disparities and examine outcomes for the most
frequent disparities. Unrelated donor-recipient pairs (n 5 4221)
who received myeloablative predominantly marrow (92%)trans-
plants for hematological malignancies (AML, ALL, CML, MDS
and NHL) through the NMDP between 1990 and 2002 were stud-
ied. High resolution HLA typing was performed for HLA-A, -B, -
C, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1. When HLA-A, -
B, -C and -DRB1 were matched, overall survival was the same if
pairs were also matched for HLA-DQ and -DP (reference), had
HLA-DP mismatches (OR 1.00, CI 0.84–1.18), or had HLA-DP
and/or -DQ mismatches (OR 1.01, CI 0.80–1.29). These groups
were combined to create the reference group for subsequent com-
parisons. Transplants with a single HLA-A disparity (n 5 317)
were associated with increased mortality (OR 1.32, CI 1.07–1.63).
The most frequent single HLA-A mismatches were HLA-
A*0201-*0205 (n 5 28), HLA-A *0301-*0302 (n 5 15), HLA-A
*0201-*0206 (n 5 15), HLA-A *0201-*6801 (n 5 12), HLA-
A*0101-*1101 (n 5 11), HLA-A*0101-*0201 (n 5 9), and HLA-
A*2402-*2403 (n5 9). Considering p5 0.01 as a threshold for sig-
nificance with multiple comparisons, there were no statistically sig-
nificant relationships between any of these disparities and transplant
outcomes. Table 1 shows the observations for the most interesting
mismatches for grades 3–4 acute GvHD: A*2402–2403 (p5 0.034)
and A*0201–0206 (p 5 0.033). There were no significant relation-
ships detected for engraftment, chronic GvHD, relapse, trans-
plant-related mortality, or disease-free survival. Using these data,
it is estimated that more than 15,000 subjects would be required
to achieve 80% power to detect an effect on survival for a particular
HLA-A disparity (assuming similar HLA-A frequencies). To over-
come this barrier, a novel system for ranking HLA disparities which
uses the structural basis for allorecognition is proposed.
Table 1. Frequent HLA-A Disparities and Transplant Outcomes
HLA Mismatch Severe Acute GvHD SurvivalA*2402-2403 OR 4.70 (CI 0.91–30.4) OR 3.02 (CI 0.56–16.3)
A*0201-0206 OR 3.22 (CI 1.02–10.50) OR 2.64 (CI 0.81–8.38)37
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Umbilical cord blood (UCB) transplantation is a promising alter-
native source of hematopoietic stem cells for patients lacking HLA-
matched donors. Nearly 60% of UCB transplants to date have been
performed on minority individuals for whom an unrelated donor
was not available; moreover, the naı¨ve phenotype of UCB cells is re-sponsible for the lower incidence and reduced severity of GvHD in
these patients. Still, relatively low cell numbers in UCB grafts have
lead to delayed immune reconstitution and higher mortality due to
infection. Reactivation of latent viruses such as CMV and EBV are
particularly problematic, as is overt infection from adenovirus
(Adv). Previous studies have shown that prophylactic adoptive im-
munotherapy with peripheral blood-derived CTL directed against
EBV, CMV and Adv can effectively prevent the clinical manifesta-
tions of these viruses after hematopoietic stem cell transplant. We
now hypothesize that generating virus-specific CTL from UCB
for adoptive immunotherapy will restore anti-viral immunity and
reduce viral infection post UCB transplant. Our aim was to generate
multi-virus specific CTL from UCB mononuclear cells using a clin-
ical-grade recombinant adenovirus type 5 vector pseudotyped with
a type 35 fiber carrying a transgene for CMVpp65. With this
Ad5f35pp65 vector we transduced UCB-derived dendritic cells to
use as antigen presenting cells to stimulate virus-specific CTL fol-
lowed by 2 rounds of weekly stimulation with autologous UCB-de-
rived EBV-lymphoblastoid cell lines (LCL) transduced with the
same vector. After 3 rounds of stimulation, 5 CTL cultures con-
tained a mean of 87% (range 81–94%) CD81ve and a mean of
26% (range 12–40%) CD41ve cells. Evaluable CTL lines showed
significant cytotoxicity in chromium release assays against non-
transduced autologous LCL and LCL infected with the
Ad5f35pp65 and Ad5f35 vectors. The observed cytotoxicity was
specific because transduced and non-transduced MHC-mismatched
LCL were not killed. ELISPOT assays on CTL demonstrated
a mean of 260 (range 45–694) and 47 (range 0–128) numbers of cells
secreting IFNg following incubation with CMVpp65 and Adv
hexon peptides respectively. No significant response to CMVIE1
peptides was demonstrated. These results show that, despite the
generally naı¨ve nature of UCB lymphocytes, multi-virus-specific re-
sponses can be expanded in vitro, and could potentially be used clin-
ically in UCBT patients who develop infectious complications prior
to immune reconstitution.
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ALLOANERGIZED HLA-MISMATCHED BONE MARROW TRANSPLANTA-
TION – LOW INCIDENCE OF CLINICALLY SIGNIFICANT GVHD AND VIRAL
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We have previously reported early results of a clinical study of
HLA-mismatched related donor bone marrow transplantation
(BMT) after ex vivo stimulation with recipient alloantigens and
co-stimulatory blockade (CSB) to induce allospecific anergy (hypo-
responsiveness) in donor T cells. We now report the long-term fol-
low-up of a larger cohort of 24 pediatric and adult patients (median
age 11 years (range 0.5–50) with high-risk hematological malignan-
cies or bone marrow failure syndromes who received HLA-mis-
matched alloanergized BMT from related donors. After
myeloablative conditioning with cyclophosphamide and total
body irradiation, patients received donor bone marrow that had
been incubated with irradiated recipient peripheral blood mononu-
clear cells and monoclonal antibodies blocking CD28-mediated co-
stimulation. 21 of 22 evaluable patients engrafted (95%) and all
achieved full donor chimerism by D 1 21. No secondary graft fail-
ure occurred. Despite receiving a median of 2.8  107/kg CD31
donor T cells (range 0.7–6.8), only 2/21 evaluable patients (10%)
developed steroid-refractory acute graft versus-host-disease
(GvHD), with only one death attributable to acute GvHD. Five
of 11 seropositive patients reactivated CMV, but only one required
extended antiviral treatment. No deaths were attributable to CMV
or other viral infections. Only 1/12 evaluable patients (8%) devel-
oped chronic GvHD, which resolved with conventional immuno-
suppressive therapy. Eight recipients (33%) of full haplotype-
mismatched BMT survive disease-free with no chronic GvHD
and with normal performance scores with a median follow-up of 8
years. HLA-mismatched alloanergized BMT is thus associated
with a low incidence of clinically significant viral infections and ste-
roid-refractory acute GvHD. Furthermore, this strategy is associ-
ated with a very low incidence of chronic GvHD, and results in
long-term failure-free survival with good quality of life in
